The effects of caffeine in adults with neurogenic orthostatic hypotension: a systematic review.
Caffeine
Neurogenic orthostatic hypotension
Postural hypotension
Journal
Clinical autonomic research : official journal of the Clinical Autonomic Research Society
ISSN: 1619-1560
Titre abrégé: Clin Auton Res
Pays: Germany
ID NLM: 9106549
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
received:
05
05
2021
accepted:
12
06
2021
pubmed:
19
6
2021
medline:
25
11
2021
entrez:
18
6
2021
Statut:
ppublish
Résumé
To systematically review the evidence base for the effectiveness and safety of caffeine for the treatment of neurogenic orthostatic hypotension in adults. Eight electronic databases were searched in January 2021. Original research studies or case reports involving adults with neurogenic orthostatic hypotension were included if caffeine was an intervention and outcomes included symptoms, blood pressure or adverse effects. Relevant studies were screened and underwent qualitative analysis. Insufficient reporting precluded meta-analysis. Five studies were identified: four crossover studies and one case report summation. Study size ranged from 5 to 16 participants. Participants had neurogenic orthostatic hypotension, with a mean standing systolic blood pressure of 86 mmHg. Two studies evaluated caffeine alone. Three studies administered caffeine in combination with ergotamine. Caffeine dose ranged from 100 to 300 mg. Nature and timing of outcomes measured varied between studies, with measurements being recorded from 30 to 480 min after intervention. Caffeine/ergotamine improved symptoms in one study and reduced orthostatic blood pressure drop in two studies. Caffeine/ergotamine increased seated blood pressure in three studies, whilst the results for caffeine alone were inconsistent. No serious adverse events were reported. All studies demonstrated high risk of bias. Caffeine should only be considered as a treatment for adults with neurogenic orthostatic hypotension when evidence-based treatments have been exhausted. PROSPERO ID: CRD42020124589. Date of registration: 30/10/2020.
Identifiants
pubmed: 34143333
doi: 10.1007/s10286-021-00814-5
pii: 10.1007/s10286-021-00814-5
pmc: PMC8212790
doi:
Substances chimiques
Caffeine
3G6A5W338E
Types de publication
Journal Article
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
499-509Informations de copyright
© 2021. The Author(s).
Références
Freeman R et al (2011) Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res 21(2):69–72
pubmed: 21431947
Mol A et al (2018) Orthostatic hypotension and physical functioning in older adults: a systematic review and meta-analysis. Ageing Res Rev 48:122–144
pubmed: 30394339
Gibbon JR, Frith J (2020) Orthostatic hypotension: a pragmatic guide to diagnosis and treatment. Drug Ther Bull 58(11):166
pubmed: 33127610
Saedon NI, Pin Tan M, Frith J (2020) The prevalence of orthostatic hypotension: a systematic review and meta-analysis. J Gerontol A Biol Sci Med Sci 75(1):117–122
pubmed: 30169579
Freeman R et al (2018) Orthostatic hypotension: JACC state-of-the-art review. J Am Coll Cardiol 72(11):1294–1309
pubmed: 30190008
Nicolopoulos K et al (2020) Association between habitual coffee consumption and multiple disease outcomes: a Mendelian randomisation phenome-wide association study in the UK Biobank. Clin Nutr 39(11):3467–3476
pubmed: 32284183
Grosso G et al (2017) Coffee, caffeine, and health outcomes: an umbrella review. Annu Rev Nutr 37(1):131–156
pubmed: 28826374
Echeverri D et al (2010) Caffeine’s vascular mechanisms of action. Int J Vasc Med. https://doi.org/10.1155/2010/834060
pubmed: 21188209
pmcid: 3003984
van Dam RM, Hu FB, Willett WC (2020) Coffee, caffeine, and health. N Engl J Med 383(4):369–378
pubmed: 32706535
Eschlböck S, Wenning G, Fanciulli A (2017) Evidence-based treatment of neurogenic orthostatic hypotension and related symptoms. J Neural Transm (Vienna) 124(12):1567–1605
Gupta V, Lipsitz LA (2007) Orthostatic hypotension in the elderly: diagnosis and treatment. Am J Med 120(10):841–847
pubmed: 17904451
Kaufmann H (1996) Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy. Neurology 46(5):1470
Thomas J et al (2020) Cochrane handbook for systematic reviews of interventions, 2nd edn. Wiley-Blackwell, Hoboken
Dewey RB Jr et al (1998) Ergotamine/caffeine treatment of orthostatic hypotension in parkinsonism with autonomic failure. Eur J Neurol 5(6):593–599
pubmed: 10210895
Hoeldtke RD et al (1986) Treatment of orthostatic hypotension with dihydroergotamine and caffeine. Ann Intern Med 105(2):168–173
pubmed: 3729199
Onrot J et al (1985) Hemodynamic and humoral effects of caffeine in autonomic failure. Therapeutic implications for postprandial hypotension. N Engl J Med 313(9):549–554
pubmed: 3894971
Arnold AC et al (2014) Combination ergotamine and caffeine improves seated blood pressure and presyncopal symptoms in autonomic failure. Front Physiol 5:270
pubmed: 25104940
pmcid: 4109567
Jordan J et al (1998) Contrasting actions of pressor agents in severe autonomic failure. Am J Med 105(2):116–124
pubmed: 9727818
Schmidt R, Fanchamps A (1974) Effect of caffeine on intestinal absorption of ergotamine in man. Eur J Clin Pharmacol 7(3):213–216
pubmed: 4851611
Kaufmann H et al (2012) The Orthostatic Hypotension Questionnaire (OHQ): validation of a novel symptom assessment scale. Clin Auton Res 22(2):79–90
pubmed: 22045363
Sismondo S (2008) Pharmaceutical company funding and its consequences: a qualitative systematic review. Contemp Clin Trials 29(2):109–113
pubmed: 17919992
Strassheim V et al (2016) Droxidopa for orthostatic hypotension: a systematic review and meta-analysis. J Hypertens 34(10):1933–1941
pubmed: 27442791